A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

NCT04440943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Breast Cancer
Gastric Cancer
Renal Cell Carcinoma
Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Cholangiocarcinoma
Bladder Urothelial Carcinoma
MSI-H Colorectal Cancer
Esophageal Cancer
Hepatic Cancer
Head and Neck Cancer
Other Solid Tumors

Interventions

DRUG: CDX-527

Sponsor

Celldex Therapeutics